Maxim initiated coverage of FibroBiologics with a Buy rating and $12 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics engages Southern Star Research as CRO in Australia
- FibroBiologics Engages Southern Star Research as CRO in Australia
- FibroBiologics files patent application for fibroblast cell-based technology
- FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
- FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference